How Afyren biotech goes industrial by opening its first factory

by bold-lichterman

Afyren is a biotech, which produces bio-based molecules intended in particular for the human nutrition and cosmetics market. These molecules aim to reduce the use of petroleum derivatives in these sectors while considerably reducing CO2 emissions. Nicolas Sordet, president and co-founder of Afyren, announces the construction of their first plant: a biorefinery with the objective of zero waste and low carbon in the Grand Est region.

Afyren was founded in 2012. “ During these first 8 years, we had this industrial objective. In our first factory, we will hire around 50 people. Our goal is to build our factories and operate them. We wish to build two complementary factories in the coming years ”, claims Nicolas Sordet.

Funding of 80 million euros

The Afyren Neoxy factory is the result of an industrial joint venture between Afyren and the SPI fund of Bpifrance which holds 49% of the capital. Funding of more than 80 million euros from public and private support, including the European Community, the Grand Est region were necessary for the realization of this project as well as two years of preparation.

Find the full interview with Nicolas Sordet, president and co-founder of Afyren:

  • DECODE VC: discover the best investors, their vision, their practices
  • DECODE Exit: how does a business transfer work? Discover the underside of startup sales
  • DECODE CTO: discover the CTOs of the most beautiful French Tech startups and companies
  • HR DECODE: discover the most inspiring HRDs and their best practices
  • Decode of the week: Richard Menneveux and his guests decipher Tech news around the world
  • WildCard: our sniper Joseph Postec shares his look on Tech news in an offbeat tone
  • Silicon Carne: the news of the Valley as seen by Carlos Diaz and his guests